Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®),
a new class of bispecific protein therapeutics designed for the treatment of chronic
hepatitis B virus (HBV) infection (CHB). This is the first in-human study of IMC-I109V in
persons with CHB.